Fibroblast  ||| S:0 E:11 ||| JJ
growth  ||| S:11 E:18 ||| NN
factor-21  ||| S:18 E:28 ||| CD
concentration  ||| S:28 E:42 ||| NN
in  ||| S:42 E:45 ||| IN
serum  ||| S:45 E:51 ||| NN
and  ||| S:51 E:55 ||| CC
synovial  ||| S:55 E:64 ||| JJ
fluid  ||| S:64 E:70 ||| NN
is  ||| S:70 E:73 ||| VBZ
associated  ||| S:73 E:84 ||| VBN
with  ||| S:84 E:89 ||| IN
radiographic  ||| S:89 E:102 ||| JJ
bone  ||| S:102 E:107 ||| NN
loss  ||| S:107 E:112 ||| NN
of  ||| S:112 E:115 ||| IN
knee  ||| S:115 E:120 ||| NN
osteoarthritis  ||| S:120 E:135 ||| VBD
We  ||| S:135 E:138 ||| PRP
aimed  ||| S:138 E:144 ||| VBD
to  ||| S:144 E:147 ||| TO
evaluate  ||| S:147 E:156 ||| VB
whether  ||| S:156 E:164 ||| IN
FGF-21  ||| S:164 E:171 ||| CD
concentration  ||| S:171 E:185 ||| NN
in  ||| S:185 E:188 ||| IN
serum  ||| S:188 E:194 ||| NN
and  ||| S:194 E:198 ||| CC
synovial  ||| S:198 E:207 ||| JJ
fluid  ||| S:207 E:213 ||| NN
( ||| S:213 E:214 ||| -LRB-
SF ||| S:214 E:216 ||| NNP
)  ||| S:216 E:218 ||| -RRB-
is  ||| S:218 E:221 ||| VBZ
associated  ||| S:221 E:232 ||| VBN
with  ||| S:232 E:237 ||| IN
radiographic  ||| S:237 E:250 ||| JJ
bone  ||| S:250 E:255 ||| NN
loss  ||| S:255 E:260 ||| NN
of  ||| S:260 E:263 ||| IN
knee  ||| S:263 E:268 ||| JJ
osteoarthritis  ||| S:268 E:283 ||| NNS
( ||| S:283 E:284 ||| -LRB-
OA ||| S:284 E:286 ||| NNP
) ||| S:286 E:287 ||| -RRB-
.  ||| S:287 E:289 ||| .
A  ||| S:289 E:291 ||| DT
total  ||| S:291 E:297 ||| NN
of  ||| S:297 E:300 ||| IN
186  ||| S:300 E:304 ||| CD
OA  ||| S:304 E:307 ||| NN
patients  ||| S:307 E:316 ||| NNS
and  ||| S:316 E:320 ||| CC
108  ||| S:320 E:324 ||| CD
controls  ||| S:324 E:333 ||| NNS
were  ||| S:333 E:338 ||| VBD
recruited ||| S:338 E:347 ||| VBN
.  ||| S:347 E:349 ||| .
The  ||| S:349 E:353 ||| DT
radiographic  ||| S:353 E:366 ||| JJ
bone  ||| S:366 E:371 ||| NN
loss  ||| S:371 E:376 ||| NN
of  ||| S:376 E:379 ||| IN
knee  ||| S:379 E:384 ||| JJ
OA  ||| S:384 E:387 ||| NNP
was  ||| S:387 E:391 ||| VBD
assessed  ||| S:391 E:400 ||| VBN
by  ||| S:400 E:403 ||| IN
the  ||| S:403 E:407 ||| DT
Ahlbäck  ||| S:407 E:415 ||| JJ
grading  ||| S:415 E:423 ||| JJ
scale ||| S:423 E:428 ||| NN
.  ||| S:428 E:430 ||| .
FGF-21  ||| S:430 E:437 ||| NNP
concentration  ||| S:437 E:451 ||| NN
in  ||| S:451 E:454 ||| IN
serum  ||| S:454 E:460 ||| NN
and  ||| S:460 E:464 ||| CC
SF  ||| S:464 E:467 ||| NNP
was  ||| S:467 E:471 ||| VBD
measured  ||| S:471 E:480 ||| VBN
by  ||| S:480 E:483 ||| IN
enzyme-linked  ||| S:483 E:497 ||| JJ
immunosorbent  ||| S:497 E:511 ||| JJ
assay  ||| S:511 E:517 ||| NNS
( ||| S:517 E:518 ||| -LRB-
ELISA ||| S:518 E:523 ||| NNP
) ||| S:523 E:524 ||| -RRB-
.  ||| S:524 E:526 ||| .
We  ||| S:526 E:529 ||| PRP
demonstrated  ||| S:529 E:542 ||| VBD
that  ||| S:542 E:547 ||| IN
OA  ||| S:547 E:550 ||| NNP
patients  ||| S:550 E:559 ||| NNS
had  ||| S:559 E:563 ||| VBD
significantly  ||| S:563 E:577 ||| RB
higher  ||| S:577 E:584 ||| RBR
serum  ||| S:584 E:590 ||| JJ
FGF-21  ||| S:590 E:597 ||| CD
concentration  ||| S:597 E:611 ||| NN
compared  ||| S:611 E:620 ||| VBN
with  ||| S:620 E:625 ||| IN
controls  ||| S:625 E:634 ||| NNS
( ||| S:634 E:635 ||| -LRB-
204.30  ||| S:635 E:642 ||| NNP
[ ||| S:642 E:643 ||| -LRB-
range  ||| S:643 E:649 ||| NN
158.25-279.16 ||| S:649 E:662 ||| CD
]  ||| S:662 E:664 ||| -RRB-
ng ||| S:664 E:666 ||| FW
/ ||| S:666 E:667 ||| FW
L  ||| S:667 E:669 ||| FW
vs.  ||| S:669 E:673 ||| FW
130.72  ||| S:673 E:680 ||| FW
[ ||| S:680 E:681 ||| -LRB-
range  ||| S:681 E:687 ||| NN
94.93-218.03 ||| S:687 E:699 ||| CD
]  ||| S:699 E:701 ||| -RRB-
ng ||| S:701 E:703 ||| FW
/ ||| S:703 E:704 ||| FW
L ||| S:704 E:705 ||| NNP
,  ||| S:705 E:707 ||| ,
p  ||| S:707 E:709 ||| CD
< ||| S:709 E:711 ||| SYM
0.01 ||| S:711 E:715 ||| CD
) ||| S:715 E:716 ||| -RRB-
.  ||| S:716 E:718 ||| .
FGF-21  ||| S:718 E:725 ||| NNP
concentration  ||| S:725 E:739 ||| NN
in  ||| S:739 E:742 ||| IN
serum  ||| S:742 E:748 ||| NN
was  ||| S:748 E:752 ||| VBD
well  ||| S:752 E:757 ||| RB
correlated  ||| S:757 E:768 ||| VBN
with  ||| S:768 E:773 ||| IN
that  ||| S:773 E:778 ||| DT
in  ||| S:778 E:781 ||| IN
paired  ||| S:781 E:788 ||| JJ
SF  ||| S:788 E:791 ||| NNP
samples  ||| S:791 E:799 ||| NNS
( ||| S:799 E:800 ||| -LRB-
r  ||| S:800 E:802 ||| LS
=  ||| S:802 E:804 ||| SYM
0.668 ||| S:804 E:809 ||| CD
,  ||| S:809 E:811 ||| ,
p  ||| S:811 E:813 ||| CD
< ||| S:813 E:815 ||| SYM
0.001 ||| S:815 E:820 ||| CD
) ||| S:820 E:821 ||| -RRB-
.  ||| S:821 E:823 ||| .
In  ||| S:823 E:826 ||| IN
OA  ||| S:826 E:829 ||| NNP
patients ||| S:829 E:837 ||| NNS
,  ||| S:837 E:839 ||| ,
those  ||| S:839 E:845 ||| DT
with  ||| S:845 E:850 ||| IN
a  ||| S:850 E:852 ||| DT
higher  ||| S:852 E:859 ||| JJR
Ahlbäck  ||| S:859 E:867 ||| JJ
grade  ||| S:867 E:873 ||| NN
had  ||| S:873 E:877 ||| VBD
significantly  ||| S:877 E:891 ||| RB
higher  ||| S:891 E:898 ||| JJR
serum  ||| S:898 E:904 ||| NNS
and  ||| S:904 E:908 ||| CC
SF  ||| S:908 E:911 ||| NNP
FGF-21  ||| S:911 E:918 ||| NNP
concentration  ||| S:918 E:932 ||| NN
( ||| S:932 E:933 ||| -LRB-
p  ||| S:933 E:935 ||| JJ
< ||| S:935 E:937 ||| SYM
0.001  ||| S:937 E:943 ||| NN
for  ||| S:943 E:947 ||| IN
both ||| S:947 E:951 ||| DT
) ||| S:951 E:952 ||| -RRB-
.  ||| S:952 E:954 ||| .
FGF-21  ||| S:954 E:961 ||| NNP
concentration  ||| S:961 E:975 ||| NN
in  ||| S:975 E:978 ||| IN
serum  ||| S:978 E:984 ||| NN
and  ||| S:984 E:988 ||| CC
SF  ||| S:988 E:991 ||| NNP
was  ||| S:991 E:995 ||| VBD
significantly  ||| S:995 E:1009 ||| RB
and  ||| S:1009 E:1013 ||| CC
independently  ||| S:1013 E:1027 ||| RB
associated  ||| S:1027 E:1038 ||| VBN
with  ||| S:1038 E:1043 ||| IN
the  ||| S:1043 E:1047 ||| DT
Ahlbäck  ||| S:1047 E:1055 ||| JJ
grade  ||| S:1055 E:1061 ||| NN
( ||| S:1061 E:1062 ||| -LRB-
r  ||| S:1062 E:1064 ||| LS
=  ||| S:1064 E:1066 ||| SYM
0.403 ||| S:1066 E:1071 ||| CD
,  ||| S:1071 E:1073 ||| ,
p  ||| S:1073 E:1075 ||| JJ
< ||| S:1075 E:1077 ||| SYM
0.001  ||| S:1077 E:1083 ||| NN
and  ||| S:1083 E:1087 ||| CC
r  ||| S:1087 E:1089 ||| LS
=  ||| S:1089 E:1091 ||| SYM
0.410 ||| S:1091 E:1096 ||| CD
,  ||| S:1096 E:1098 ||| ,
p  ||| S:1098 E:1100 ||| CD
< ||| S:1100 E:1102 ||| SYM
0.001 ||| S:1102 E:1107 ||| CD
;  ||| S:1107 E:1109 ||| :
respectively ||| S:1109 E:1121 ||| RB
) ||| S:1121 E:1122 ||| -RRB-
.  ||| S:1122 E:1124 ||| .
These  ||| S:1124 E:1130 ||| DT
findings  ||| S:1130 E:1139 ||| NNS
indicated  ||| S:1139 E:1149 ||| VBD
that  ||| S:1149 E:1154 ||| IN
FGF-21  ||| S:1154 E:1161 ||| NNP
might  ||| S:1161 E:1167 ||| MD
be  ||| S:1167 E:1170 ||| VB
a  ||| S:1170 E:1172 ||| DT
potential  ||| S:1172 E:1182 ||| JJ
biomarker  ||| S:1182 E:1192 ||| NN
for  ||| S:1192 E:1196 ||| IN
predicting  ||| S:1196 E:1207 ||| VBG
bone  ||| S:1207 E:1212 ||| NN
loss  ||| S:1212 E:1217 ||| NN
of  ||| S:1217 E:1220 ||| IN
OA ||| S:1220 E:1222 ||| NNP
.  ||| S:1222 E:1224 ||| .
Therapeutic  ||| S:1224 E:1236 ||| JJ
interventions  ||| S:1236 E:1250 ||| NNS
by  ||| S:1250 E:1253 ||| IN
blocking  ||| S:1253 E:1262 ||| VBG
FGF-21  ||| S:1262 E:1269 ||| CD
signaling  ||| S:1269 E:1279 ||| JJ
pathways  ||| S:1279 E:1288 ||| NN
to  ||| S:1288 E:1291 ||| TO
delay  ||| S:1291 E:1297 ||| VB
the  ||| S:1297 E:1301 ||| DT
degenerative  ||| S:1301 E:1314 ||| JJ
process  ||| S:1314 E:1322 ||| NN
of  ||| S:1322 E:1325 ||| IN
OA  ||| S:1325 E:1328 ||| NNP
warrants  ||| S:1328 E:1337 ||| NNS
further  ||| S:1337 E:1345 ||| JJ
investigations ||| S:1345 E:1359 ||| NNS
.  ||| S:1359 E:1361 ||| .
